## **Resource Summary Report**

Generated by FDI Lab - SciCrunch.org on Apr 12, 2025

# Rabbit Anti-Histone H3, Trimethyl (Lys27) Monoclonal Antibody, Unconjugated, Clone C36B11

RRID:AB\_2616029 Type: Antibody

#### **Proper Citation**

(Cell Signaling Technology Cat# 9733, RRID:AB\_2616029)

### **Antibody Information**

URL: http://antibodyregistry.org/AB\_2616029

Proper Citation: (Cell Signaling Technology Cat# 9733, RRID:AB\_2616029)

Target Antigen: H3

Host Organism: rabbit

**Clonality:** monoclonal

**Comments:** Applications: W, IHC-P, IF-IC, F, ChIP, ChIP-seq. Consolidation on 9/2016:

AB\_1147656, AB\_1147655.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Rabbit Anti-Histone H3, Trimethyl (Lys27) Monoclonal Antibody,

Unconjugated, Clone C36B11

**Description:** This monoclonal targets H3

Target Organism: h, m, r, mk

Clone ID: Clone C36B11

**Antibody ID:** AB\_2616029

**Vendor:** Cell Signaling Technology

Catalog Number: 9733

Alternative Catalog Numbers: 9733S, 9733P

**Record Creation Time:** 20231110T053914+0000

**Record Last Update:** 20241115T130639+0000

#### **Ratings and Alerts**

 ENCODE PROJECT External validation for lot: 1 is available under ENCODE ID: ENCAB000AQY - ENCODE https://www.encodeproject.org/antibodies/ENCAB000AQY

No alerts have been found for Rabbit Anti-Histone H3, Trimethyl (Lys27) Monoclonal Antibody, Unconjugated, Clone C36B11.

#### Data and Source Information

Source: Antibody Registry

#### **Usage and Citation Metrics**

We found 280 mentions in open access literature.

**Listed below are recent publications.** The full list is available at FDI Lab - SciCrunch.org.

Bryan E, et al. (2025) Nucleosomal asymmetry shapes histone mark binding and promotes poising at bivalent domains. Molecular cell, 85(3), 471.

Cigrang M, et al. (2025) Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity. Nature communications, 16(1), 512.

Wang J, et al. (2024) BRG1 programs PRC2-complex repression and controls oligodendrocyte differentiation and remyelination. The Journal of cell biology, 223(7).

Veronezi GMB, et al. (2024) Nucleation and spreading maintain Polycomb domains every cell cycle. Cell reports, 43(4), 114090.

Boddu PC, et al. (2024) Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape. Molecular cell, 84(8), 1475.

Visamol S, et al. (2024) EZH2 as a major histone methyltransferase in PDGF-BB-activated orbital fibroblast in the pathogenesis of Graves' ophthalmopathy. Scientific reports, 14(1),

Chen Y, et al. (2024) SP6 controls human cytotrophoblast fate decisions and trophoblast stem cell establishment by targeting MSX2 regulatory elements. Developmental cell, 59(12), 1506.

Chapman G, et al. (2024) Defining cis-regulatory elements and transcription factors that control human cortical interneuron development. iScience, 27(6), 109967.

Janssens DH, et al. (2024) Scalable single-cell profiling of chromatin modifications with sciCUT&Tag. Nature protocols, 19(1), 83.

Zhang Y, et al. (2024) Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer. Cell metabolism, 36(1), 193.

Zhang M, et al. (2024) ZNF143 deletion alters enhancer/promoter looping and CTCF/cohesin geometry. Cell reports, 43(1), 113663.

Shi W, et al. (2024) Lactic acid induces transcriptional repression of macrophage inflammatory response via histone acetylation. Cell reports, 43(2), 113746.

Katznelson A, et al. (2024) A fluorescence-based protocol to quantitatively titrate CUT&RUN buffer components. STAR protocols, 5(1), 102866.

DuCote TJ, et al. (2024) EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas. Cancer research communications, 4(2), 388.

Liu CC, et al. (2024) Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer. Cell reports. Medicine, 5(2), 101396.

Shin D, et al. (2024) Thalamocortical organoids enable in vitro modeling of 22q11.2 microdeletion associated with neuropsychiatric disorders. Cell stem cell, 31(3), 421.

Ye X, et al. (2024) Enhancer-promoter activation by the Kaposi sarcoma-associated herpesvirus episome maintenance protein LANA. Cell reports, 43(3), 113888.

Kim H, et al. (2024) MTOR modulation induces selective perturbations in histone methylation which influence the anti-proliferative effects of mTOR inhibitors. iScience, 27(3), 109188.

Abu-Zaid A, et al. (2024) Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. Cell reports. Medicine, 5(3), 101468.

Lin CT, et al. (2024) Protein degradation of Lsd1 is mediated by Bre1 yet opposed by Lsd1-interacting IncRNAs during fly follicle development. iScience, 27(5), 109683.